Literature DB >> 21404460

Elevated transcript levels from the MDM2 P1 promoter and low p53 transcript levels are associated with poor prognosis in human pancreatic ductal adenocarcinoma.

Lukasz Filip Grochola1, Helge Taubert, Thomas Greither, Umesh Bhanot, Andrej Udelnow, Peter Würl.   

Abstract

UNLABELLED: OBJECTDIVES: Mouse double minute 2 is a key negative regulator of the p53 protein, a central node in the mediation of tumor suppression. The MDM2 gene contains 2 differently regulated promoters, MDM2-P1 and MDM2-P2, which differ strongly in their biological and clinical importance.
METHODS: We assess the clinical significance of the expression of messenger RNA (mRNA) transcripts originating from both MDM2 promoters, measured with quantitative reverse transcription polymerase chain reaction in microdissected tissues from 57 patients with pancreatic ductal adenocarcinoma (PDAC). Furthermore, we determine the clinical relevance of p53 mRNA transcript expression and incorporate the somatic p53 mutational status into our analyses.
RESULTS: Interestingly, elevated transcript levels from the P1 promoter, but not the P2 promoter, associate significantly with up to 6.3-fold increased relative risk for tumor-related death (Cox multivariate analysis: P = 0.013). Furthermore, transcripts originating from both MDM2 promoters are found to correlate significantly with p53 mRNA levels (up to r = 0.315; P = 0.017). In addition, low p53 mRNA expression associates with worse PDAC prognosis (relative risk = 2.28; P = 0.021).
CONCLUSIONS: This study presents the first differentiated analysis of the MDM2-P1, MDM2-P2, and p53 transcript expression in human PDAC and demonstrates the significant clinical implications of those transcripts. Furthermore, it suggests an additional facet in the regulation of MDM2 via its P1 promoter in this malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21404460     DOI: 10.1097/mpa.0b013e3181f95104

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  11 in total

1.  Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.

Authors:  Yixuan Ma; Sina Sender; Anett Sekora; Weibo Kong; Peter Bauer; Najim Ameziane; Susann Krake; Mandy Radefeldt; Ruslan Al-Ali; Frank Ulrich Weiss; Markus M Lerch; Alisha Parveen; Dietmar Zechner; Christian Junghanss; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2022-04-16       Impact factor: 6.208

2.  Netrin-1 promoted pancreatic cancer cell proliferation by upregulation of Mdm2.

Authors:  Qian Huang; Hong-Wei Hua; Feng Jiang; Dai-He Liu; Gang Ding
Journal:  Tumour Biol       Date:  2014-07-08

3.  Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.

Authors:  Yasuki Hori; Katsuyuki Miyabe; Michihiro Yoshida; Takahiro Nakazawa; Kazuki Hayashi; Itaru Naitoh; Shuya Shimizu; Hiromu Kondo; Yuji Nishi; Shuichiro Umemura; Akihisa Kato; Hirotaka Ohara; Hiroshi Inagaki; Takashi Joh
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

4.  The use of multidimensional data to identify the molecular biomarker for pancreatic ductal adenocarcinoma.

Authors:  Liwei Zhuang; Yue Qi; Yun Wu; Nannan Liu; Yili Fu
Journal:  Biomed Res Int       Date:  2013-09-21       Impact factor: 3.411

5.  Low dose arsenite confers resistance to UV induced apoptosis via p53-MDM2 pathway in ketatinocytes.

Authors:  Y Zhou; W Zeng; M Qi; Y Duan; J Su; S Zhao; W Zhong; M Gao; F Li; Y He; X Hu; X Xu; X Chen; C Peng; J Zhang
Journal:  Oncogenesis       Date:  2017-08-07       Impact factor: 7.485

Review 6.  KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.

Authors:  Jonas Cicenas; Kotryna Kvederaviciute; Ingrida Meskinyte; Edita Meskinyte-Kausiliene; Aiste Skeberdyte; Jonas Cicenas
Journal:  Cancers (Basel)       Date:  2017-04-28       Impact factor: 6.639

7.  Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage.

Authors:  Hamid A Bakshi; Mazhar S Al Zoubi; Faruck L Hakkim; Alaa A A Aljabali; Firas A Rabi; Amin A Hafiz; Khalid M Al-Batanyeh; Bahaa Al-Trad; Prawej Ansari; Mohamed M Nasef; Nitin B Charbe; Saurabh Satija; Meenu Mehta; Vijay Mishra; Gaurav Gupta; Salem Abobaker; Poonam Negi; Ibrahim M Azzouz; Ashref Ali K Dardouri; Harish Dureja; Parteek Prasher; Dinesh K Chellappan; Kamal Dua; Mateus Webba da Silva; Mohamed El Tanani; Paul A McCarron; Murtaza M Tambuwala
Journal:  Nutrients       Date:  2020-06-26       Impact factor: 5.717

8.  Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

Authors:  Danielle C Glassman; Randze L Palmaira; Christina M Covington; Avni M Desai; Geoffrey Y Ku; Jia Li; James J Harding; Anna M Varghese; Eileen M O'Reilly; Kenneth H Yu
Journal:  BMC Cancer       Date:  2018-06-27       Impact factor: 4.430

9.  MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.

Authors:  Ying Chen; Dan-Dan Wang; Ye-Ping Wu; Dan Su; Tian-Yi Zhou; Ren-Hua Gai; Ying-Ying Fu; Lin Zheng; Qiao-Jun He; Hong Zhu; Bo Yang
Journal:  Br J Cancer       Date:  2017-08-17       Impact factor: 9.075

Review 10.  Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.

Authors:  Toshinori Ozaki; Meng Yu; Danjing Yin; Dan Sun; Yuyan Zhu; Youquan Bu; Meixiang Sang
Journal:  BMC Cancer       Date:  2018-03-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.